My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

123.09 +0.80 (+0.65%)
Streaming Delayed Price Updated: 1:52 PM EDT, Sep 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
48 49 Next >
Novartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance
Novartis raises 2025 sales and profit forecast as key drugs drive strong Q1 results; core operating income up 23% to $5.6 billion on higher net sales. 
Via Benzinga
Topics Earnings
Novartis Creeps Toward A Breakout On Its Beat-And-Raise
Shares are consolidating and are now trading above their 50-day and 200-day lines. 
Via Investor's Business Daily
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this... 
Via Benzinga
General Motors, Coca-Cola And 3 Stocks To Watch Heading Into Tuesday
 
Via Benzinga
Earnings Scheduled For April 29, 2025
 
Via Benzinga
Earnings Preview For Novartis
 
Via Benzinga
Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report
Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and... 
Via Stocktwits
Topics Government Intellectual Property Lawsuit
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion. 
Via MarketBeat
Topics Artificial Intelligence Economy Government
The Smartest International Stock ETF to Buy With $100 Right Now
It could be time for international stocks to shine, making this ETF a must-own. 
Via The Motley Fool
Topics ETFs Economy
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
Via The Motley Fool
Topics Economy Government Lawsuit
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
NOVARTIS AG-SPONSORED ADR has a stellar value proposition. NYSE:NVS not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states. 
Via Benzinga
S&P 500, Nasdaq Futures Rise After Stocks Dip Amid Trump's Jabs At Powell, Strong Yen Gives Nikkei A Volatile Start
U.S. stock futures rose Monday night even as Wall Street had a rough start to the week, amid growing concerns regarding the Federal Reserve's independence, and President Donald Trump's repeated attacks... 
Via Benzinga
Topics Economy Government Stocks
3 Momentum Stocks That Could Soar Post-Market Volatility
Three unexpected companies have rallied quickly in the period following tariff-related market turbulence; can they maintain momentum? 
Via MarketBeat
Topics Artificial Intelligence World Trade
Food for Thought: Results from a Food Allergy Survey of Caregivers
(BPT) - What is it like for millions of American families managing food allergies? To better understand these experiences, Genentech, a member of the Roche Group, and the Novartis Pharmaceuticals... 
Via Brandpoint
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
Via The Motley Fool
Topics Government World Trade
Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties
Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S. medicines domestically and add thousands of jobs. 
Via Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks. 
Via Benzinga
Topics World Trade
3 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support traditional approval. 
Via Benzinga
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval
The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage. 
Via Investor's Business Daily
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction. 
Via Benzinga
The Top 3 Vanguard ETFs of 2025 (so Far) Share This 1 Striking Common Denominator
Via The Motley Fool
Topics Bonds ETFs
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Technical Analysis observations.
Exploring NOVARTIS AG-SPONSORED ADR's Technical Signals and Breakout Potential: Promising Signs: NOVARTIS AG-SPONSORED ADR Setting the Stage for a Breakout. 
Via Chartmill
No Fear And No Panic After A 10% Correction = No Bottom
In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off. 
Via Talk Markets
Topics Stocks / Equities
FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool
FDA approves Novartis' Pluvicto for advanced prostate cancer patients who have received ARPI therapy. 
Via Benzinga
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is an undervalued gem with solid fundamentals.
NOVARTIS AG-SPONSORED ADR has caught the attention as a great value stock. NYSE:NVS excels in profitability, solvency, and liquidity, all while being very reasonably priced. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
48 49 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.